Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies (ITCI) Stock Price & Analysis


ITCI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$42.01 - $66.00
Previous Close$45.96
Average Volume (3M)687.21K
Market Cap
Enterprise Value$3.81B
Total Cash (Recent Filing)$591.90M
Total Debt (Recent Filing)$20.04M
Price to Earnings (P/E)-16.8
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding94,705,054
10 Day Avg. Volume676,672
30 Day Avg. Volume687,213
Standard Deviation0.36
Financial Highlights & Ratios
Price to Book (P/B)6.91
Price to Sales (P/S)29.29
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-20.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.28
Enterprise Value/Gross Profit16.65
Enterprise Value/Ebitda-14.48
Price Target Upside55.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $42.01 and its highest was $66.00 in the past 12 months.
    What is Intra-Cellular Therapies’s market cap?
    Currently, no data Available
    When is Intra-Cellular Therapies’s upcoming earnings report date?
    Intra-Cellular Therapies’s upcoming earnings report date is May 10, 2023 which is in 50 days.
      How were Intra-Cellular Therapies’s earnings last quarter?
      Intra-Cellular Therapies released its earnings results on Mar 01, 2023. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.592 by $0.142.
        Is Intra-Cellular Therapies overvalued?
        According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Intra-Cellular Therapies pay dividends?
          Intra-Cellular Therapies does not currently pay dividends.
          What is Intra-Cellular Therapies’s EPS estimate?
          Intra-Cellular Therapies’s EPS estimate is -$0.62.
            How many shares outstanding does Intra-Cellular Therapies have?
            Intra-Cellular Therapies has 95,280,010 shares outstanding.
              What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
              Intra-Cellular Therapies reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.592. Following the earnings report the stock price went up 0.591%.
                Which hedge fund is a major shareholder of Intra-Cellular Therapies?
                Among the largest hedge funds holding Intra-Cellular Therapies’s share is Woodline Partners LP. It holds Intra-Cellular Therapies’s shares valued at 21M.


                  Intra-Cellular Therapies Stock Smart Score

                  The Intra-Cellular Therapies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Intra-Cellular Therapies

                  Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Royalty Pharma
                  Elanco Animal Health

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis